Human lymphocyte antigen reactivity modified by neuraminidase

Area of Science:

• Immunology
• Cell Biology

Background:

• Human lymphocytes express Human Leukocyte Antigen (HLA) molecules on their surface.
• Antibodies can bind to HLA antigens, potentially leading to cell lysis.
• Neuraminidase is an enzyme that can modify cell surface glycoproteins.

Purpose of the Study:

• To investigate the effect of neuraminidase treatment on human lymphocyte susceptibility to antibody-mediated lysis.
• To determine if neuraminidase treatment enhances lysis by anti-HLA antibodies.
• To explore the specificity of antibody-mediated lysis on enzyme-treated cells.

Main Methods:

• Human lymphocytes were treated with neuraminidase from Vibrio cholera.
• Cells were subsequently incubated with antiserums directed against HLA antigens.
• Cytotoxicity tests were performed to assess cell lysis.
• Control cells were incubated in buffer without enzyme treatment.
• Enzyme-treated cells were also cultured for 2-6 days to observe changes in sensitivity.

Main Results:

• Neuraminidase-treated lymphocytes showed increased susceptibility to lysis by anti-HLA antiserums compared to control cells.
• Enzyme-treated cells were also lysed by antibodies not directed against HLA antigens, which did not affect control cells.
• The heightened sensitivity to antibody-mediated lysis diminished within 2 to 6 days of tissue culture.

Conclusions:

• Neuraminidase treatment of human lymphocytes enhances their susceptibility to antibody-mediated lysis, particularly involving HLA antigens.
• This enzymatic modification exposes or alters targets recognized by a broader range of antibodies.
• The effect of neuraminidase on lymphocyte sensitivity is transient, suggesting a reversible modification of cell surface components.